review · Medicine
Communication between the gut microbiota and the brain operates bidirectionally, significantly influencing neurological and mental health. The vast community of microorganisms in the gastrointestinal tract contributes vital roles to digestion, metabolic functions, immune regulation, and cognitive processes. Imbalances in this microbial community, known as dysbiosis, represent risk factors for conditions including depression, anxiety, autism spectrum disorder, Parkinson's disease, and Alzheimer's disease. Interventions targeted at the microbiome, such as prebiotics, probiotics, dietary changes, and faecal microbiota transplantation, present pathways to alleviate symptoms by re-establishing microbial equilibrium, modulating immune pathways, and adjusting neurotransmitter production. Additionally, advanced delivery systems, including microbially derived nanoparticles and targeted probiotics, offer potential to enhance the precision and effectiveness of pharmaceutical treatments, though clinical adoption requires addressing ethical issues, unforeseen effects, and clinical optimisation.
Disruptions in gut microbes are increasingly connected to major brain and mental health disorders. Understanding and targeting the gut-brain axis opens up non-invasive treatment options, such as specialised diets or microbial transplants, which could improve quality of life for individuals suffering from conditions like depression, autism, or Parkinson's disease.
Potential applications include novel therapeutics, dietary supplements, and drug delivery systems such as microbially derived nanoparticles targeting specific gut environments. These solutions would be used by pharmaceutical developers, clinicians, and healthcare providers. The work represents early-stage to translational concepts, as practical clinical implementation still requires addressing ethical considerations, treatment optimisation, and potential unintended side effects.
AI-generated from the published abstract. Always read the original work before citing.
Over the last several years, the gut microbiota-brain axis has been the focus of medical study, demonstrating the bidirectional nature of gut and brain communication and the resulting influence on neurological and mental health. Trillions of microorganisms, particularly those found in the gastrointestinal tract, contribute the most to the pathophysiology recovery of organs that are critical to human health, such as digestive processes and metabolism, immune responses, and even cognitive function. Dysbiosis (a disturbance in the microbiome balance) has been identified as one of the risk factors for neuropsychiatric illnesses such as depression, anxiety, autism spectrum disorder, Parkinson's disease, and Alzheimer's disease. Therapeutic strategies aimed at the gut microbiota, such as probiotics, dietary modifications, prebiotics, and fecal microbiota transplantation, will eventually offer ways to alleviate symptoms associated with these disorders by restoring microbial balance, modulating the immune response, and influencing the production of major neurotransmitters. Innovative drug carriers, such as microbially-derived nanoparticles and probiotics that target particular parts of the gut or microbial communities, may improve pharmaceutical treatment efficacy and specificity. The resolution of difficulties such as ethical concerns, unexpected repercussions, and peak performance optimization in a clinical setting is critical for the advancement of this subject.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1097/md.0000000000043542
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
